New York esophageal squamous cell carcinoma 1 (NY-ESO-1) (NY-ESO-1)

New York esophageal squamous cell carcinoma 1 (NY-ESO-1), encoded by the CTAG1B gene, is a prominent member of the cancer-testis antigen (CTA) family (UniProt P78358). Under normal physiological conditions, its expression is restricted to the germ cells of the testis and occasionally the fetal ovary, where it is sequestered from the immune system due to the lack of HLA expression on these cells (Gnjatic et al., 2006, Adv Cancer Res). However, NY-ESO-1 is aberrantly re-expressed in a wide range of malignancies, including synovial sarcoma, melanoma, and multiple myeloma, making it a highly specific target for immunotherapy (Thomas et al., 2018, Front Immunol). Because NY-ESO-1 is an intracellular protein, it is primarily targeted via T-cell receptor (TCR) engineered T-cells or vaccines that recognize NY-ESO-1 peptides presented by Major Histocompatibility Complex (MHC) molecules, most commonly HLA-A*02:01 (D'Angelo et al., 2018, Cancer Discovery). The therapeutic landscape for NY-ESO-1 has advanced significantly with the 2024 FDA approval of afamitresgene autoleucel, the first TCR-T cell therapy for synovial sarcoma (FDA, 2024). This target is particularly valuable because its restricted expression in normal tissues minimizes the risk of on-target, off-tumor toxicity, while its high immunogenicity often triggers spontaneous immune responses in patients (Chen et al., 1997, PNAS). Clinical trials continue to explore NY-ESO-1 targeting in various solid and hematological tumors, often combining TCR-T therapies with checkpoint inhibitors to enhance efficacy. Monitoring for NY-ESO-1 expression and HLA compatibility is essential for patient selection in these advanced cellular therapies.

Other names

Cancer/testis antigen 1BCTAG1BLAGE-2ESO1CT6.1Cancer/testis antigen 1

T-cell receptor (TCR) engineered T-cell therapy recognizing HLA-presented peptides; Cancer vaccines inducing humoral and cellular immunity